Evidence Based Research | Patient Resources

Withania Somnifera, also known as Ashwagandha, Winter Cherry and Indian Ginseng, is one of the “SUPER” Adaptogens coming to us from Ayurvedic Herbal Medicine with 8,000 years of recorded use1. It is what I call a “Super Adaptogen” because, along with a few other herbs like Korean Ginseng, Rhodiola and Siberian Ginseng, all have very powerful effects on virtually every system in the human body in addition to their adaptogenic effects and it sets them apart from the many...

Higher adherence to a plant-based diet is associated with a lower risk for prostate cancer progression and recurrence, according to a study presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, held from Feb. 16 to 18 in San Francisco. Study lead author Vivian Liu and her team focused on men who already had prostate cancer and were at risk of the cancer growing or returning after treatment. The plant-based sub-study research began in 2004 and involved 2,038 ...

Physicians at City of Hope, working in collaboration with scientists at Translational Genomics Research Institute (TGen), have found that greater gut microbial diversity in patients with metastatic kidney cancer is associated with better treatment outcomes on Food and Drug Administration-approved immunotherapy regimens. Their findings are outlined in a study published in the journal European Urology.
“We also reported the changes over time in the gut microbiome that occur during the c...

A well-established link has been documented between periodontal disease and cardiovascular diseases like atherosclerosis, coronary heart disease, and acute coronary events, including myocardial infarction. Many studies have associated periodontal disease with elevated bacterial exposure, coronary heart disease, and early atherogenesis.  Recent research published in 2019 showed—for the first time—the common presence of bacterial DNA from viridans streptococci in aspirate...

Results from a placebo-controlled, randomised, double-blind, 3-arm clinical trial has shown that evening dosing of melatonin may prolong survival in Non-Small Cells lung cancer patients.  Eighty-four advanced (stage IIIB or IV) NSCLC patients receiving identical dosing of standard etoposide/cisplatin therapy, between the ages of 18 and 80 years. The Study:
Patients were randomly assigned to 1 of 3 arms: Placebo at 8 a.m. and 8 p.m. 20 mg melatonin at 8 a.m. and placebo at 8 p.m. Pl...